Antibiotic Administration in Pediatric Febrile Neutropenia

Febrile neutropenia is a common and potentially life-threatening complication of chemotherapy in children, defined by the occurrence of fever in the context of an abnormally low neutrophil count. Prompt empiric administration of broad-spectrum antibiotics has long been established as the cornerstone of management, with many centres aiming to deliver the first dose within 60 minutes of presentation. Advances in risk stratification now allow clinicians to distinguish low-risk from high-risk patients, enabling outpatient oral regimens or abbreviated inpatient courses for selected children while reserving aggressive intravenous therapies for those at greatest risk of severe infection. International efforts have led to the development of care bundles and clinical pathways that integrate rapid diagnostic tests, standardised antibiotic protocols and quality-improvement metrics. Despite this progress, definitions of ‘prompt’ therapy vary across institutions, and considerable uncertainty persists around optimal antibiotic choice, duration and the role of de-escalation. Global collaborations continue to refine guidelines that balance the urgent need to prevent sepsis with judicious use of antibiotics to limit toxicity and resistance.

Research from Nature Portfolio

Recent prospective analyses have challenged the universality of tight time-to-antibiotic targets by demonstrating that, in paediatric patients presenting without overt organ dysfunction, delays beyond conventional benchmarks did not predict worse clinical outcomes once triage bias was accounted for. A multicentre cohort study of over 260 febrile neutropenia episodes reported a median delay of two hours to antibiotic initiation and found no clear link between this interval and rates of severe sepsis or intensive care admission in non-critically ill children. These findings prompt reconsideration of fixed thresholds and support more nuanced, risk-adjusted triage protocols that prioritise rapid treatment for those most vulnerable while avoiding undue pressure on overburdened emergency pathways.

Antibiotic Administration in Pediatric Febrile Neutropenia publication trend

The graph below shows the total number of articles in antibiotic administration in pediatric febrile neutropenia across all publications each year (not limited to Nature Index journals).

Technical terms

Febrile neutropenia: Simultaneous presence of fever and an absolute neutrophil count below 0.5×10^9/L, indicating high risk of severe bacterial infection.

Time to antibiotics (TTA): Interval between recognition of fever or arrival at a healthcare setting and administration of the first antibiotic dose.

Broad-spectrum antibiotics: Antimicrobials active against a wide range of bacterial species, used empirically before pathogen identification.

Triage bias: Systematic distortion in evaluating treatment delays and outcomes, arising when sicker patients receive more rapid intervention.

Care bundle: A set of evidence-based practices grouped together to improve patient outcomes through standardisation.

References

1. Time to antibiotics is unrelated to outcome in pediatric patients with fever in neutropenia presenting without severe disease during chemotherapy for cancer. Scientific Reports (2022).
2. Interventions aiming to reduce time to antibiotics (TTA) in patients with fever and neutropenia during chemotherapy for cancer (FN), a systematic review. Supportive Care in Cancer (2019).
3. Optimizing Time to Antibiotic Administration in Children with Possible Febrile Neutropenia through Quality Improvement Methodologies. Pediatric Quality and Safety (2019).
4. Overcoming challenges to reduce time to antibiotic therapy in febrile neutropenic children: insights from a Mexican center. Hematology Transfusion and Cell Therapy (2024).